Latest News and Press Releases

First Immunotherapeutic Candidate to Leverage Selecta’s Proprietary Synthetic Vaccine Particle (SVP™) PlatformSEL-212 Targeting Unmet Needs of Chronic Refractory and Tophaceous Gout PatientsInitial...

Data underscore potential of SVP-Rapamycin to enhance therapeutic benefit of gene therapies by mitigating unwanted humoral (antibody) and cellular immune responses WATERTOWN, Mass., Oct. 20, 2016 ...

WATERTOWN, Mass., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune...

Demonstrated clinical activity in Phase 1 program of SEL-212Advanced two proprietary gene therapy programs based on the same SVP-Rapamycin immunotherapy as SEL-212Successfully completed Initial...

WATERTOWN, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies, today...

WATERTOWN, Mass., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies, will...

Published results from preclinical studies show the potential of Selecta’s proprietary SVP-Rapamycin (SEL-110) immune therapy to improve the efficacy and safety of biologic therapeuticsThe data...

WATERTOWN, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for...

Selecta announces gene therapy programs for Methylmalonic Acidemia (MMA) and Ornithine Transcarbamylase Deficiency (OTC)  Selecta is advancing these gene therapy programs with collaborators...

WATERTOWN, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB) today announced the closing of its initial public offering of 5,000,000 shares of common stock at a...